Viela Bio, Inc is a biotechnology business based in the US. Viela Bio shares (VIE) are listed on the NASDAQ and all prices are listed in US Dollars. Viela Bio employs 170 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Viela Bio
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – VIE – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Viela Bio stock price (NASDAQ: VIE)Use our graph to track the performance of VIE stocks over time.
Viela Bio shares at a glance
|52-week range||$21.30 - $53.83|
|50-day moving average||$53.07|
|200-day moving average||$39.12|
|Wall St. target price||$53.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-78.90|
Buy Viela Bio shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Viela Bio stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Viela Bio financials
|Revenue TTM||$11.7 million|
|Gross profit TTM||$9.6 million|
|Return on assets TTM||-23.83%|
|Return on equity TTM||-41.26%|
|Market capitalisation||$2.9 billion|
TTM: trailing 12 months
Shorting Viela Bio shares
There are currently 1.9 million Viela Bio shares held short by investors – that's known as Viela Bio's "short interest". This figure is 9.6% down from 2.1 million last month.
There are a few different ways that this level of interest in shorting Viela Bio shares can be evaluated.
Viela Bio's "short interest ratio" (SIR)
Viela Bio's "short interest ratio" (SIR) is the quantity of Viela Bio shares currently shorted divided by the average quantity of Viela Bio shares traded daily (recently around 1.8 million). Viela Bio's SIR currently stands at 1.09. In other words for every 100,000 Viela Bio shares traded daily on the market, roughly 1090 shares are currently held short.
However Viela Bio's short interest can also be evaluated against the total number of Viela Bio shares, or, against the total number of tradable Viela Bio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Viela Bio's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Viela Bio shares in existence, roughly 30 shares are currently held short) or 0.0788% of the tradable shares (for every 100,000 tradable Viela Bio shares, roughly 79 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Viela Bio.
Find out more about how you can short Viela Bio stock.
Viela Bio share dividends
We're not expecting Viela Bio to pay a dividend over the next 12 months.
Viela Bio overview
Viela Bio, Inc. , a clinical-stage biotechnology company, engages in the research and development of treatments for severe inflammation and autoimmune diseases in the United States. The company's lead product candidate is inebilizumab, a humanized monoclonal antibody for neuromyelitis optica spectrum disorder; and which is in Phase III trials for patients with myasthenia gravis and IgG4-related diseases, as well as in Phase II trial for kidney transplant desensitization. It is also developing VIB4920 that is in Phase II trial for kidney transplantation rejection and rheumatoid arthritis, as well as in Phase IIb trial for sjögren's syndrome; and VIB7734, which is in Phase Ib trial for cutaneous lupus erythematosus, in Phase I trial for COVID-19-related acute lung injury, and a planned Phase II tria for systemic lupus erythematosus. The company's pre-clinical research and development product candidates include VIB1116 to decrease the number and function of antigen-presenting dendritic cells; and a mAb cytokine fusion protein to inhibit inflammatory responses. Viela Bio, Inc. has a strategic collaboration with Hansoh Pharmaceutical Group Company Limited and Mitsubishi Tanabe Pharma Corporation to develop and commercialize inebilizumab for autoimmune diseases in China, Hong Kong, Macau, Japan, Thailand, South Korea, Indonesia, Vietnam, Malaysia, the Philippines, Singapore, and Taiwan.
Stocks similar to Viela Bio
Viela Bio in the news
Frequently asked questionsWhat percentage of Viela Bio is owned by insiders or institutions?
Currently 55.079% of Viela Bio shares are held by insiders and 47.165% by institutions. How many people work for Viela Bio?
Latest data suggests 170 work at Viela Bio. When does the fiscal year end for Viela Bio?
Viela Bio's fiscal year ends in December. Where is Viela Bio based?
Viela Bio's address is: One MedImmune Way, Gaithersburg, MD, United States, 20878 What is Viela Bio's ISIN number?
Viela Bio's international securities identification number is: US9266131005 What is Viela Bio's CUSIP number?
Viela Bio's Committee on Uniform Securities Identification Procedures number is: 926613100
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert